Beta Bionics Key KPI Miss Targets, Analyst Flags Valuation Risks

Diabetes management solutions provider, Beta Bionics Inc. (NASDAQ:BBNX), on Thursday reported preliminary fourth-quarter 2025 results showing strong revenue growth, driven by rapid expansion in its Pharmacy Benefit Plan channel and a growing installed user base for its diabetes management technology.The company said net sales for the quarter are expected to reach at least $32 million, versus the consensus of $28.19 million, representing a year-over-year increase of at least 56%.Sales through the Durable Med ...